| Abstract |
Background: The regulated degradation of intracellular proteins plays an essential role in most biological processes, especially in the control of cell proliferation and differentiation. In eukaryotic cells, intracellular proteolysis is ensured largely by a multi-enzyme system, called the ubiquitin / proteasome system. This system involves hundreds of components that allow the recognition and labeling of proteins destined to degradation by the 26S proteasome. The aim of this work was to analyze and establish a link between the concentration of the proteasome and its catalytic activity in both serum and intracellular level in a wide range of patients with different hematological neoplastic in a Moroccan population newly diagnosed. Methods: Proteasome levels were measured using a sandwichELISAassay in normal donorsand in patients with Acute andChronic Leukemia, multiple myeloma, lymphoma. Results: The increase of serum proteasome levels was more pronounced in patients with myeloma (7112 ± 733 ng / ml).The catalytic activity of circulating proteasomewas very low as well in controls than in patients.The intracellular proteasome has revealed an optimal value in individuals suffering from chronic leukemia (6303 ± 726 ng/ml), followed by patients with multiple myeloma (5910±336 ng/ml).Theactivity of intracellular chymotrypsin-like of proteasome was more important in the patients. Conclusions: Althoughthe serum proteasome level is a potential new tool for the monitoring of patients with liquid cancer, the intracellular assay proves to be beneficial since it allows a dosage at the source and allows estimating the predictive toxicity risk score in patient treatment.
KEYWORDS: Proteasome,moroccan patients,hematological malignancies, subcellular, serum, ELISA technique.
|
